This study is in progress, not accepting new patients
Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis
Summary
- Eligibility
- for people ages 18-75 (full criteria)
- Location
- at San Diego, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- AbbVie
- Links
- This clinical study may be evaluating a usage that is not currently FDA approved. Please see US Prescribing Information for approved uses.
- ID
- NCT04195698
- Phase
- Phase 3 Atopic Dermatitis (Eczema) Research Study
- Study Type
- Interventional
- Participants
- Expecting 485 study participants
- Last Updated